Intellia Therapeutics Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based Treatment September 29, 2020 - NASDAQ Companies 0 Bay Street News » View More News for September 29, 2020